Carol D. Karp
Net Worth
Last updated:
What is Carol D. Karp net worth?
The estimated net worth of Ms. Carol D. Karp is at least $7,767,628 as of 4 Oct 2023. She owns shares worth $5,649 as insider, has earned $5,264,419 from insider trading and has received compensation worth at least $2,497,560 in Prothena Corporation plc.
What is the salary of Carol D. Karp?
Ms. Carol D. Karp salary is $624,390 per year as Chief Regulatory Officer in Prothena Corporation plc.
How old is Carol D. Karp?
Ms. Carol D. Karp is 72 years old, born in 1953.
What stocks does Carol D. Karp currently own?
As insider, Ms. Carol D. Karp owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Prothena Corporation plc (PRTA) | Chief Regulatory Officer | 663 | $8.52 | $5,649 |
What does Prothena Corporation plc do?
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Carol D. Karp insider trading
Prothena Corporation plc
Ms. Carol D. Karp has made 16 insider trades between 2021-2023, according to the Form 4 filled with the SEC.
The largest trade she's ever made was exercising 15,000 units of PRTA stock on 7 Jun 2023. As of 4 Oct 2023 she still owns at least 663 units of PRTA stock.
Prothena Corporation key executives
Prothena Corporation plc executives and other stock owners filed with the SEC:
- Dr. Gene G. Kinney Ph.D. (56) Pres, Chief Executive Officer & Director
- Mr. Brandon S. Smith (50) Chief Operating Officer
- Mr. Michael J. Malecek (59) Chief Legal Officer & Company Sec.
- Mr. Tran B. Nguyen M.B.A. (51) Chief Financial Officer & Chief Strategy Officer
- Ms. Carol D. Karp (72) Chief Regulatory Officer